ADCETRIS

Dr. Clay Siegall is Leading in the Development of Effective Medications for Cancer

Dr. Clay Siegall is a respected expert in the field of medical research. He founded a biotech firm known as Seattle Genetics. This biotech giant specializes in developing targeted therapy drugs, meant for ailments that have shown insignificant mortality improvement in history. Cancer has been the primary disease targeted by the medical research carried out by Seattle Genetics. Under Dr. Clay’s leadership as the CEO and the Chairman of the Board, Seattle Genetics has grown into a global biotechnology powerhouse.

 

Dr. Clay Siegall’s education and career

 

Dr. Clay is a proud graduate of the well-known University of Maryland where he attained a B.S. in Zoology. At George Washington University, he undertook a doctoral research in genetics. Between 1988 and 1991, he was holding a senior role at National Cancer Institute and National Institutes of Health. Dr. Clay Siegall later became a researcher at Bristol-Myers Squibb Pharmaceutical between 1991 and 1997. In 1998, he unveiled Seattle Genetics. Currently, Dr. Clay is one of the directors of Alder Biopharmaceuticals and Therapeutics.

 

Achievements of Seattle Genetics

 

Cancer patients have immense unmet medical requirements. Dr. Clay describes this as his motive in venturing into pharmaceutical research. He believes that chemotherapy is outdated and there is a need for a change. He is confident that the use targeted drugs therapy will generate positive results. He regards it as more efficient. FDA approved the firm’s first antibody drug conjugate. It was the first ADC to be approved by the FDA ever. This approval is a boost for Seattle Genetics since the firm is planning to launch more ADCs in the market in future.

 

Dr. Siegall has guided Seattle Genetics into entering strategic alliances with top biotechnology and pharmaceutical firms. Currently, the biotech giant has more than 20 drugs whose production is underway. From a tiny startup managed by a few researchers, Seattle Genetics is now a dominant player in mega medical research on cancer. The remarkable growth, both financially and operational, are fruits of hard work and passion.

 

Dr. Clay Siegall is certain that his company is well-positioned in offering cancer treatment solution. He has big dreams and plans for Seattle Genetics. He is aiming to expand the list of drugs it is developing, and enhance its potential in the drug development industry.